-
$21.5M Series A financing round to advance pipeline of next-gen engineered off-the-shelf NK cell therapies
-
Funding round led by current investors Acorn Bioventures and ALSHC; joined by new investor Cormorant Asset Management
-
Financing will drive multiple pre-clinical programs through IND-enabling studies and the continued progression of a GMP manufacturing capability
CAR-T Cell Therapeutics: A Multi-Billion Dollar Market
CAR-T is a promising type of immunotherapy where doctors collect immune cells, modify them in a laboratory, and provide them the capacity to recognize and kill cancer cells. When infused into a patient, the cells get multiplied and stay in the body as “living drugs.”
Since the approval of the first CAR-T cell therapeutic in 2017, widespread research, proliferating clinical trials, aggressive M&A activity, and lucrative IPOs have created a robust CAR-T cell market. [Read more…]
The State of CAR-T Cell Therapies in 2021
Scientific progress within the field of cancer immunotherapy has led to five CAR-T cell therapy approvals: Kymriah (tisagenlecleucel), Yescarta (axicabtagene ciloleucel), Tecartus (brexucabtagene autoleucel), Breyanzi (lisocabtagene maraleucel), and Abecma (idecabtagene vicleucel). Additionally, JW Therapeutics has announced NMPA approval of Relmacabtagene Autoleucel Injection in China. This is the first CAR-T product independently developed in China and approved as a Category 1 biologics product, as well as the sixth approved CAR-T product globally. [Read more…]
JW Therapeutics Achieves Approval of Sixth CAR-T Product Globally by NMPA in China
-
The first CAR-T product independently developed in China and approved as a Category 1 biologics product, and the sixth approved CAR-T product globally
-
Currently the only approved CAR-T product that has been simultaneously included in the National Significant New Drug Development Program, granted priority review and breakthrough therapy designation
-
May provide a best-in-class CAR-T therapy in China given its demonstration of high rates of durable disease response and low rates of CAR-T associated toxicities
Axion BioSystems’ Bioelectronic Assays Aid in the Development of Cancer Immunotherapies
Author: Axion Biosystems
The immunotherapy field is booming, with cell therapies like chimeric antigen receptor (CAR) T cells taking the lead. According to one forecast, the market is expected to reach $6.1 billion in size by 2030 for CAR-T therapies alone. The FDA approved the world’s first CAR-T therapy, Kymriah, in 2017, and it is now available at over 130 treatment centers across the United States. [Read more…]
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 11
- Next Page »
